TransCode Therapeutics, Inc.
RNAZ
$8.95
-$0.34-3.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -109.19% | 17.61% | -263.27% | -44.73% | 56.20% |
| Total Depreciation and Amortization | -96.24% | -90.62% | -63.84% | -12.34% | -8.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.20% | -74.36% | 5,027.02% | 449.27% | -47.87% |
| Change in Net Operating Assets | 118.44% | -114.35% | 51.34% | 146.50% | -252.26% |
| Cash from Operations | -4.36% | -79.26% | 21.35% | 44.45% | -11.60% |
| Capital Expenditure | -- | -- | -- | -- | -180.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -180.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | 45.47% | 623.98% | -66.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -118.62% | -100.00% | 45.47% | 623.98% | -66.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.95% | -169.02% | 168.31% | 183.99% | -138.11% |